<DOC>
	<DOCNO>NCT02146833</DOCNO>
	<brief_summary>This open-label , Phase 2 clinical study oral Selective Inhibitor Nuclear Export ( SINE ) Selinexor ( KPT-330 ) patient metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>SHIP ( Selinexor Hormone Insensitive Prostate Cancer )</brief_title>
	<detailed_description>This Phase 2 , open-label study explore effect selinexor ( KPT-330 ) therapy patient metastatic castration-resistant prostate cancer ( mCRPC ) . Approximately 50 patient planned enrollment . Patients receive oral dose Selixenor one three dose schedule .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven adenocarcinoma prostate evidence skeletal metastasis bone scan and/or CT scan . Must receive lease one agent know impact survival ( abiraterone , enzalutamide , ect . ) Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 Karnofsky Performance Status ( KPS ) ≥ 60 % . Serum testosterone level &lt; 50ng/ml Ongoing gonadal androgen deprivation therapy LHRH analogues orchiectomy . Patients , orchiectomy , must maintain standard dose LHRH analogue therapy appropriate frequency duration study Progression disease despite androgen ablation show objective , documented evidence disease progression ( exclude PSA ) . Discontinuation glucocorticoid prescribe specifically treat prostate cancer ( e.g. , secondary hormonal manipulation ) &gt; 4 week prior receive first dose study drug . Glucocorticoids prescribe chronic noncancerrelated illness ( e.g. , asthma COPD ) well control medical management permissible equivalent ≤ 10 mg prednisone daily . Histologic variant adenocarcinoma primary tumor Patients require may expect require urgent treatment docetaxel study ( e.g. , patient visceral metastasis ) . Therapy hormonal therapy , include herbal product know decrease PSA level ( e.g. , Saw Palmetto PCSPES ) within 4 week prior receive first dose study drug . Therapy samarium153 , strontium89 , radium223 within 8 week prior first dose study drug . Prior external beam radiation therapy complete &lt; 3 week single fraction palliative radiotherapy within 14 day prior first dose study drug . Any `` currently active '' second malignancy , nonmelanoma skin cancer . Patients consider `` currently active '' malignancy , complete therapy consider physician least less 30 % risk relapse next 3 month . Active uncontrolled autoimmune disease may require corticosteroid therapy study Severely compromise immunological state , include know human immunodeficiency virus ( HIV ) Known acute chronic hepatitis B C Chemotherapy investigational therapy ( target immunotherapy ) require 3week washout period treatment initiation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>castrate-resistant prostate cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>KPT-330</keyword>
	<keyword>selinexor</keyword>
</DOC>